Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Scyllo-inositol - Transition Therapeutics Ireland

Drug Profile

Scyllo-inositol - Transition Therapeutics Ireland

Alternative Names: AZD-103; ELND-005; Quercinitol; Scyllitol; Scyllocyclohexanehexol; Scylloinositol

Latest Information Update: 30 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transition Therapeutics
  • Developer Speranza Therapeutics; Transition Therapeutics Ireland
  • Class Antidementias; Cyclohexanols; Nootropics; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Phase II Down syndrome
  • Discontinued Bipolar disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Jan 2018 Scyllo-inositol is still at phase II/III for Alzheimer's disease (for the treatment of agitation and aggression) in Canada, Spain, USA and United Kingdom and at phase II for Down syndrome in USA (PO) (Transition Therapeutics pipeline, January 2018)
  • 31 Aug 2016 Transition Therapeutics has been acquired by OPKO Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top